The purpose of this project is to evaluate the clinical impact of the use ofglucocorticoids beyond 10 days for patients with critical COVID-19 at MDMC.
The purpose of this project is to evaluate the clinical impact of the use of
glucocorticoids beyond 10 days for patients with critical COVID-19 at MDMC.
Glucocorticoids have become standard of care for critical COVID-19 patients, with a
mortality benefit shown in several recent randomized control trials. Critical COVID-19
can lead to ARDS, in which the use of glucocorticoids has uncertain benefit beyond 10
days. Studies have shown increased harm in the use of these agents in persistent ARDS
(≥14 days). Additionally, studies supporting the use of steroids in COVID-19 only used
steroids for a limited time (up to 10 days). Given that these agents can possibly lead to
increased patient morbidity and mortality, prolonged use of glucocorticoids is not
without risk. To date, there have been no studies evaluating the clinical impact of
glucocorticoid use beyond 10 days for treatment of critical COVID-19.
Inclusion Criteria:
- > 18 years of age
- ICU admission at any time during first hospital admission for COVID-19
- COVID-19 diagnosis
- Dexamethasone, hydrocortisone, or methylprednisolone therapy for SARS-CoV-2
infection
Exclusion Criteria:
- Prior ICU admission before study start date
- Death or hospice before day 11 of hospital admission
- Still admitted at time of data analysis from index admission
Methodist Dallas Medical Center
Dallas, Texas, United States
Investigator: Crystee Cooper, DHEd
Contact: 214-947-1280
clinicalresearch@mhd.com
Investigator: Kristen Rahmanzadeh, Pharm D
Crystee Cooper, DHEd
214-947-1280
clinicalresearch@mhd.com
Zaid Haddadin, MS
214-947-1280
clinicalresearch@mhd.com
Kristen Rahmanzadeh, PharmD, Principal Investigator
The Methodist Hospital Research Institute